Kaposi's sarcoma
================

Originally described in the late nineteenth century, Kaposi's sarcoma (KS) has become the most prevalent cancer amongst AIDS patients in the US and worldwide ([@b31-ijn-2-277]). Until recently the etiological agent of this disease remained elusive. Finally, in 1994, Chang and colleagues isolated viral DNA sequences from KS biopsies, resulting in the identification of the Kaposi's sarcoma-associated herpes virus (KSHV or HHV-8) ([@b19-ijn-2-277]). KSHV is maintained latently in all KS tumors and thus is believed to be the causative agent of the disease ([@b19-ijn-2-277]; [@b16-ijn-2-277]; [@b77-ijn-2-277]). Several forms of KS are currently recognized, including classic, endemic, iatrogenic (transplant associated), and AIDS-associated ([@b81-ijn-2-277]). Among the few cases of KS reported in the US prior to the onset of the AIDS epidemic, most were iatrogenic or found in elderly men of Mediterranean descent (classic). In contrast, endemic KS has always been prevalent in Africa, and today has become the most frequently observed pediatric cancer in this population following the rise of the HIV epidemic. AIDS-associated KS first became prevalent worldwide during the 1980s into the early 1990s in men who have sex with men. It has declined following the implementation of highly active anti-retroviral therapy (HAART), as have many other of the original AIDS-defining conditions ([@b29-ijn-2-277]; [@b12-ijn-2-277]; [@b31-ijn-2-277]). Unfortunately, HAART has had no effect on the incidence of classic, iatrogenic, or endemic KS nor is HAART available to populations who presently experience the highest prevalence of HIV, such as in Africa. More alarming, cases of AIDS-associated KS are now emerging in patients receiving HAART and who maintain adequate immune function ([@b49-ijn-2-277]; [@b11-ijn-2-277]; [@b12-ijn-2-277]). As the number of HIV-positive individuals continues to grow worldwide, KS is re-emerging as a more aggressive and prominent tumor type.

The changing nature of KS is reflected in 5-year survival data reported by the NCI Surveillance Epidemiology and End Results (SEER) program ([Figure 1](#f1-ijn-2-277){ref-type="fig"}). As mentioned above, most KS cases in the US prior to 1980 were dermal, minimally aggressive, and often associated with elderly white men. For these patients, KS was rarely life threatening and over 80% survived more than 5 years. During the height of the US HIV epidemic and prior to the onset of HAART, a more aggressive KS tumor emerged. Dramatically, 5-year survival rates in KS patients plummeted from 1985 to 1989. Following the implementation of HAART and the development of KS-specific treatment regimens (interferon alpha, taxol, and combination chemotherapy) the US witnessed a substantial decrease in patient mortality. Yet, even today, less than 50% of all KS patients in the US, ie, with ready access to HAART, reach the 5-year survival mark. The outlook is even worse for the growing number of African American KS patients. Clearly, our ability to treat KS patients both now and in the future is dependent upon the development of novel and efficacious treatment regimens against KS. Restoring immune sufficiency alone does not suffice.

Current KS therapy ranges from watchful waiting to aggressive chemotherapy and is largely dependent upon the lesion location, size, and extent. Localized, non-progressive disease is easily treated through cryotherapy, argon laser excision, local chemotherapeutic injection, or localized radiation. Response rates vary with each of these treatment regimens, but have been reported to reach up to 90% ([@b51-ijn-2-277]). For AIDS-associated and iatrogenic KS, immune reconstitution is sometimes sufficient to trigger tumor remission. HAART alone caused KS remission in 48%--86% of HIV positive KS patients ([@b54-ijn-2-277]; [@b25-ijn-2-277]; [@b26-ijn-2-277]; [@b14-ijn-2-277]; [@b61-ijn-2-277]; [@b64-ijn-2-277]; [@b90-ijn-2-277]). Similarly, iatrogenic KS can be controlled by limiting the dosage, or switching the type of immunosuppressive therapy employed. However, recent evidence suggests that immune reconstitution is not the sole factor leading to KS regression. Protease inhibitors associated with modern day HAART may also possess anti-KS activities ([@b60-ijn-2-277]). Moreover, our recent findings along with those reported by Stallone et al suggest that some immunosuppressive drugs like rapamycin may specifically target KSHV-infected tumors ([@b78-ijn-2-277]; [@b74-ijn-2-277]).

Visceral organ involvement represents the most severe manifestation of KS, and lesions have been reported in the lungs, gastrointestinal tract, lymph nodes, heart, bone, and spleen of affected individuals ([@b51-ijn-2-277]). For such disseminated or rapidly progressing forms of KS more aggressive therapies must be employed. Classically, a combination of multiple chemotherapeutics has been utilized (eg, CHOP -- cyclophosphamide, hydroxydoxorubicin, vincristine/Oncovin^®^, prednisone; ABV -- doxorubicin, bleomycin, vincristine; and BV -- bleomycin, vincristine). Alternatively, interferon alpha, paclitaxol, and etoposide effectively treat disseminated KS and are FDA-approved for this purpose ([@b69-ijn-2-277]; [@b53-ijn-2-277]; [@b50-ijn-2-277]; [@b89-ijn-2-277]; [@b39-ijn-2-277]; [@b32-ijn-2-277]). However, the side-effects of chemotherapeutic drug regimens limit their efficacy, especially in immunocompromised KS patients. Anthracycline drugs in particular (eg, doxorubicin, epirubicin, idarubicin, daunorubicin) present a secondary challenge to patient health due to their known cardiotoxic side-effects ([@b28-ijn-2-277]). In order to combat these issues, targeted drug delivery systems have been developed for several anthracycline compounds. This review focuses on the pharmaceutical advancements that have aimed to improve both the efficacy and tolerability of daunorubicin in KS treatment.

Daunorubicin
============

Originally isolated from *Streptomyces peucetius varcaesitue*, daunorubicin (DNR) has become a mainstay in modern chemotherapy ([@b23-ijn-2-277]; [@b7-ijn-2-277]). DNR belongs to the anthracycline family of compounds, which hold intrinsic antibiotic and anti-tumor activities. Structurally, anthracyclines contain a daunosamine sugar linked to naphthacene via an O-glycosidic bond (see [Figure 2](#f2-ijn-2-277){ref-type="fig"}) ([@b70-ijn-2-277]). Differences in the naphthacene derivative differentiate DNR from other anthracyclines and change the pharmacokinetic properties of the compound ([@b70-ijn-2-277]). DNR is believed to function through multiple mechanisms to mediated DNA damage ([@b76-ijn-2-277]). Intercalation of the daunosamin residue into the minor groove of cellular DNA leads to local DNA unwinding ([@b21-ijn-2-277]; [@b18-ijn-2-277]; [@b17-ijn-2-277]; [@b62-ijn-2-277]; [@b8-ijn-2-277]). It is hypothesized that these DNA--DNR complexes serve as a blockade for cellular replication. Alternatively, the activity of topoisomerase II, an enzyme that relieves torsional stress during DNA synthesis, is also significantly inhibited by DNR ([@b82-ijn-2-277]; [@b34-ijn-2-277]). Anthracyclines stabilize interaction between topoisomerase II and cleaved DNA, preventing the enzyme from fully resolving DNA breaks ([@b82-ijn-2-277]). Finally, cellular metabolism of DNR leads to the formation of free radical species capable of inducing DNA damage ([@b41-ijn-2-277]; [@b24-ijn-2-277]; [@b75-ijn-2-277]). Thus, through the non-specific targeting of DNA replication, DNR targets all cells with a high proliferation index. Cell cycle progression prior to complete repair of these DNR-induced DNA lesions can result in chromosomal instability or trigger cell death. Since normal cells of the body must also proliferate to maintain homeostasis, significant side-effects including alopecia, nausea, and vomiting are often observed in patients receiving DNR therapy. In order to alleviate some of these adverse side-effects, a liposomal DNR derivative was developed.

Liposomal formulation
=====================

Phospholipid spheres were originally discovered and termed liposomes in the 1960s ([@b6-ijn-2-277]; [@b73-ijn-2-277]). Now tailored for use in drug formulations, liposomes can be classified based on lamellarity, size, makeup, and biological distribution ([@b44-ijn-2-277]; [@b63-ijn-2-277]). Unilaminar liposomes, composed of a single lipid bilayer, are frequently used to encapsulate water soluble drugs ([@b44-ijn-2-277]), and can be further classified based on size. Small unilaminar liposomes (SUV) are typically 25--100 nm in diameter, whereas large unilaminar liposomes (LUV) are significantly bigger (100--400 nm) ([@b63-ijn-2-277]). Multilaminar liposomes (MLV) range from 100 nm to over 1 μm in size and contain several concentric lipid bilayers ([@b63-ijn-2-277]). In contrast to SUV and LUV, MLV are used frequently to package lipid soluble drugs ([@b44-ijn-2-277]).

The liposomal structure is hypothesized to stabilize encapsulated drugs in vivo. Liposomes flowing in the blood fail to extravasate intact blood vessels, accumulating instead in areas of discontinuous capillaries, such as tumor tissue ([@b47-ijn-2-277]; [@b27-ijn-2-277]; [@b45-ijn-2-277]; [@b43-ijn-2-277]). In this manner, therapeutic toxicity should be reduced while increasing tumor uptake. Moreover, since KS is a highly vascularized tumor characterized by capillary leakage, this property of liposomal drug formulations may increase therapeutic efficacy. Unfortunately, all liposomes also naturally target the reticuloendothelial system (RES) of the body, which includes the liver, spleen, and bone marrow ([@b65-ijn-2-277]; [@b45-ijn-2-277]). While circulating in the blood, liposomes bind plasma proteins, immunoglobulins, and complement leading to RES-uptake via opsinization ([@b20-ijn-2-277]; [@b22-ijn-2-277]). Extremely large liposomes, like the giant MLVs (\>1 μm), are also trapped and concentrated within the small, alveolar capillaries of the lungs ([@b46-ijn-2-277]). Certainly, it could be envisioned that liposomal uptake by the RES would have significant advantages for the delivery of potential immunomodulatory therapeutics. However, for most anti-cancer agents this property is undesirable.

Several RES-targeting liposomal drug formulations have been developed using a wide variety of strategies. These drugs have advantages over classic therapies, reducing a number of the toxicities previously associated with anthracycline administration ([@b71-ijn-2-277]). Some of the first forms of liposomal doxorubicin (LD) employed acidic lipids to draw in the weakly basic drug ([@b4-ijn-2-277]). Other approaches establish a liposomal pH gradient, pulling the drug towards the core of each lipid sphere ([@b59-ijn-2-277]; [@b56-ijn-2-277]). Such technology is utilized in the formulation of therapeutics currently on the market including Myocet^®^ (LD; Medeus Pharma) and Onco TCS^®^ (liposomal vincristine; INEX Parmaceuticals) ([@b30-ijn-2-277]; [@b36-ijn-2-277]; [@b4-ijn-2-277]). Finally, RES-targeting liposomes can be formulated to contain lipid-soluble drugs within the liposomal membrane. Notably, LEP ETU^®^, a form of liposomal paclitaxel manufactured by NeoPhar, is manufactured using this technology ([@b84-ijn-2-277]; [@b4-ijn-2-277]).

As scientists learn more about the biological properties of liposomes, it has become feasible to develop RES-avoiding drug formulations. Clearly, a reduction in RES uptake provides many pharmacokinetic and biological benefits to any chemotherapeutic. Toxicity, specificity, and plasma half-life are increased by RES avoidance. Several methodologies have been developed that limit RES exposure. Most simply, patients may be subjected to RES saturation with empty liposomes prior to therapeutic administration. This approach limits RES uptake but may have significant, long-term effects on RES function ([@b1-ijn-2-277]; [@b3-ijn-2-277]). Modeling the RES avoidance by erythrocytes, scientists have incorporated polyethylene glycol (PEG) in the lipid bilayer of some liposomes. This "stealth" technology greatly extends the drug half-life through a reduction in RES uptake (reviewed in [@b4-ijn-2-277]). Doxil, a PEG-coated form of liposomal doxorubicin (PLD), is the first FDA-approved KS therapy to employ STEALTH^®^ technology (see [Figure 3](#f3-ijn-2-277){ref-type="fig"}). This approach as well as other RES-avoiding technologies including DaunoXome^®^ (liposomal daunorubicin; DNX) have been highly successful and represent a wave of newly formulated liposomal therapeutics.

Already new technology is being developed to further the targeting specificity of liposomal carriers. Cationic liposomes show high affinity for tumor neovasculature and may demonstrate increased efficacy for highly angiogenic tumor types ([@b83-ijn-2-277]). In addition, scientists are working to incorporate specific receptors, tumor ligands, and antibodies in future liposomal drug formulations. These modifications should lead to the development of tumor-specific therapies with limited side-effects and maximum efficacy.

Pharmacology and kinetics
=========================

DaunoXome^®^, a liposomal formulation of DNR (DNX), was first licensed in the United Kingdom in 1995 and later approved by the FDA. This liposomal formulation, manufactured by Gilead Pharmaceuticals Inc. (San Dimas, CA), is uniquely formulated to be RES-avoiding. Specifically, DNX is the first liposomal derivative of its kind to be made solely of lipids ([@b4-ijn-2-277]). Composed of three major components: distearoylphosphatidylcholine (DPC), cholesterol, and DNR, DNX liposomes are small (45 nm) and neutrally charged (Gilead Sciences 2000; [@b4-ijn-2-277]). Formulation of DNR into a citrate salt assists in drug encapsulation. Due to the small size and relative neutrality of DNX particles, RES uptake is minimized, leading to prolonged drug circulation ([@b33-ijn-2-277]). However, in murine model systems, RES absorption of DNX remains 60%--110% higher than that observed during conventional DNR therapy (Gilead Sciences 2000).

Evidence that the pharmacokinetics of DNX would differ greatly from those observed with conventional DNR first came from murine xenograft models. In preclinical trials, mice with lymphosarcoma (P-1798)-derived tumors or mammary adenocarcinoma (MA16C)-derived tumors were treated and monitored for DNX pharmacokinetics ([@b33-ijn-2-277]). Plasma DNR levels were consistently higher in DNX-treated mice compared with conventional DNR. Clearance of free DNR occurred rapidly (44.9 mL/h) compared with the liposomal formulation (0.195 mL/h). Although the rate of tumor drug accumulation was much higher in mice treated with conventional therapy (k~a~ = 2.64/h) than those receiving DNX (k~a~ = 0.265/h), area under the curve (AUC) values increased 10 times with the liposomal formulation. Differences in pulmonary and cardiac uptake were negligible, suggesting that toxicity to these organs would be limited. As a result, tumor progression as well as mortality significantly decreased in DNX-treated mice. The authors attribute the plasma stability of liposomal DNR to the incorporation of high phase transition temperature of DPC and the addition of cholesterol to the encapsulating lipid bilayer. This stability is required to maintain elevated DNX serum levels long enough to allow for effective tumor uptake. Once entrapped in the fenestrated capillaries of the tumor, DNR becomes bioavailable and functions to effectively limit tumor growth. These tumor-specific targeting properties made liposomal DNR attractive for future clinical studies.

Following the success of DNX in animal models, several clinical trials examined the pharmacokinetic properties of this novel drug formulation in patients. At the time, KS was emerging as a serious threat to the growing number of AIDS patients worldwide. Even though animal models of KS did not become available until recently ([@b5-ijn-2-277]) and, therefore, DNX was never tested preclinically in a bona fide KS-model, there was a strong push to get FDA approval. For this reason, the properties of DNX in KS patients were examined by several groups. The first study, reported in 1995, examined the pharmacokinetics, response, and toxicity of increasing DNX dosages ([@b38-ijn-2-277]). From these data, a dosage between 40 and 60 mg/m^2^ was shown to be most efficacious. As a result the recommended DNX dosage was set to 40 mg/m^2^ every 2 weeks, a standard which still holds true today (Gilead Sciences 2000). At these levels, reports of mean plasma AUC range from 114.91 to 120.1 μg h^--1^ mL^--1^ ([@b38-ijn-2-277]; [@b35-ijn-2-277]). These data represent an 11- to 12-fold increase over conventional DNR and reflect the stability of the liposomal carrier as previously described in murine model systems ([@b33-ijn-2-277]; [@b38-ijn-2-277]). Likewise, clearance is significantly reduced in DNX treated patients when compared with those treated with conventional drug (10.5 mL/min vs 233 mL/min, respectively) ([@b2-ijn-2-277]; [@b38-ijn-2-277]; [@b35-ijn-2-277]). These two properties combine to stabilize serum DNX, resulting in a half life between 4 and 5.6 h (t~1/2~ DNR ≈ 0.77 h) ([@b38-ijn-2-277]; [@b35-ijn-2-277]). Peak plasma levels range from 14.8 to 22 μg/mL and far surpass those previously observed with conventional DNR treatment ([@b2-ijn-2-277]; [@b38-ijn-2-277]; [@b35-ijn-2-277]). These results suggest that the increased stability of liposomal DNR may provide a mechanism by which high cumulative doses may be administered to patients without serious side-effects. As a result, the efficacy and tolerability of DNX was anticipated to surpass all previous DNR formulations.

Efficacy in KS treatment
========================

Evaluation of the efficacy of an individual KS treatment modality is largely dependent upon the implementation of standard of staging criteria. Unfortunately, many of the initial DNX studies were conducted before the implementation of the Aids Clinical Trials Groups (ACTG) response criteria. In 1989 Krown et al proposed this standard method of staging to assess KS response to clinical trial regimens ([@b50-ijn-2-277]). The scope of KS involvement is often difficult to assess and may be confounded by other underlying conditions, especially in the context of HIV-AIDS. Determining the extent of visceral disease can be difficult and in the past has been scored mainly upon the severity of patient symptoms. The ACTG criteria have defined a distinct and stringent set of characteristics to classify therapeutic response (see [Table 1](#t1-ijn-2-277){ref-type="table"}). Specifically, the appearance of any new lesion or the progression of any KS-related symptom excludes patients from achieving either complete or partial response even if as a whole, the individual experiences a therapeutic benefit ([@b50-ijn-2-277]). As a result of these stricter criteria, studies conducted using ACTG guidelines show a significant decrease in patient response rates compared with studies conducted using non-standard evaluation criteria ([@b40-ijn-2-277]). Even with the implementation of the ACTG guidelines, many factors may influence the reported success rate of individual trials, including patient CD4 count, treatment history, and concurrent drug administration ([@b66-ijn-2-277]; [@b38-ijn-2-277]; [@b35-ijn-2-277]; [@b72-ijn-2-277]).

The first DNX trials focused on the safety and potential therapeutic benefits of liposomal DNR in the treatment of AIDS-associated KS. Three separate phase I/II clinical trials monitored the response of over 115 HIV-positive KS patients ([@b66-ijn-2-277]; [@b38-ijn-2-277]; [@b85-ijn-2-277]). The severity of KS varied greatly among the study participants, but most patients were classified as having highly aggressive disease. Previous treatment with chemotherapy was not used as an exclusion parameter. Once drug safety was established at lower doses ([@b66-ijn-2-277]; [@b38-ijn-2-277]), study participants were treated every 2 weeks with 40--60 mg/m^2^ i.v. DNX. Overall response rates (representing those with complete or partial tumor regression), as determined by differential standards, varied from 55% to 60% ([@b66-ijn-2-277]; [@b38-ijn-2-277]; [@b85-ijn-2-277]). Response of pulmonary KS alone was even higher, wherein 75% of study participants experienced complete or partial response according to ACTG standards ([@b85-ijn-2-277]). These results, which showed disease regression with few side-effects, provided a rationale to pursue DNX as a novel KS therapy.

The ABV regimen is a classic first-line defense against aggressive or disseminated KS. In clinical trials, the response rates to such combination drug therapy are reported to range from 33% to 88% ([@b51-ijn-2-277]). To compare the efficacy of DNX with conventional ABV, Gill and colleagues performed a prospective study of 227 HIV-positive KS patients ([@b40-ijn-2-277]). Study participants were randomized to two treatment arms, 40 mg/m^2^ DNX or ABV (10 mg/m^2^ doxorubicin, 15U bleomycin, 1 mg vincristine) every 2 weeks. Only patients with advanced KS and no prior systemic chemotherapy were admitted into the trial. All localized treatments had to be discontinued at least 14 days before study enrollment. Surprisingly, ACTG response rates between the two arms of the trial were comparable (25% and 27.9% for DNX and ABV, respectively) with most patients achieving stable disease (58%--62%). No significant difference was observed in time to progression or survival. Complete remission was documented in both DNX- and ABV-treated study participants. Together, these data show that DNX efficacy is not distinguishable from that of conventional, multi-drug ABV therapy.

AIDS-associated KS represents a unique challenge wherein the decision to implement HAART in addition to chemotherapeutic regimens needs to be considered. In fact, in AIDS-associated lymphoma HAART can be delayed until all chemotherapy cycles have been concluded. Even though concomitant administration of HAART and combination-chemotherapy is considered safe and effective ([@b68-ijn-2-277]), the use of AZT with chemotherapy was previously contraindicated ([@b57-ijn-2-277]). Importantly, withholding HAART during chemotherapy is safe, allows for the administration of higher dose therapy, and does not modulate AIDS progression ([@b58-ijn-2-277]). Whether these lymphoma-specific recommendations also applied to DNX administration in KS was previously unknown.

Protease inhibitors are known to block the activity of cytochrome p450~IIIA4~ (CYP3A4), which metabolizes anthracycline drugs ([@b88-ijn-2-277]). Due to this property, the efficacy of anthracyclin therapy in combination with HAART was formerly questioned. The emergence of HAART-resistant HIV strains has since led to the desire to maintain anti-retroviral treatment during the course of anthracycline administration. To determine the ramifications of proteasome inhibitor co-administration, Fumagalli and colleagues examined DNX pharmacokinetics in the presence or absence of HAART ([@b35-ijn-2-277]). Eighteen individuals with rapidly progressing visceral, pulmonary, gastrointestinal, or mucocutaneous KS were enrolled in the study. Of the participants, 39% had undergone prior chemotherapy. Although the pharmacokinetic properties of DNX (delivered at 40 mg/m^2^) were unaltered by concomitant administration of any nucleoside reverse transcriptase inhibitor (NRTI)-protease inhibitor cocktail, prior anthracycline therapy significantly increased both peak DNX concentration and plasma AUC. These data suggest that prior chemotherapeutic treatments may influence DNX efficacy. Regardless, most study participants (82.3%) achieved either complete or partial response. Together, these findings suggest that HAART does not influence DNX efficacy; however, the effect of anthracyline therapy on the activity of protease inhibitors remains to be addressed.

Although these trials demonstrate that DNX is efficacious in the treatment of AIDS-associated KS, several patient attributes clearly effect therapeutic outcome. Recent reports suggest that prior administration of anthracyline therapy modulates both drug pharmacokinetics and KS response ([@b66-ijn-2-277]; [@b38-ijn-2-277]; [@b35-ijn-2-277]). Gill and colleagues examined this observation in detail, finding that prior chemotherapy as a whole does not influence patient response ([@b38-ijn-2-277]). However, in study participants previously treated with anthracycline therapies, a significant difference in therapeutic efficacy was observed (p = 0.004) ([@b38-ijn-2-277]). Whether these observations can be attributed to therapeutic resistance or differences in DNX kinetics is unclear; however, it is clear that patient treatment history may influence the choice to begin liposomal DNR treatment. CD4 count also appears to affect DNX efficacy. Patients with a CD4 count below 100 have a significantly lower probability of responding to DNX therapy (p = 0.004), suggesting that control of HIV is essential to successful KS treatment ([@b38-ijn-2-277]). Clearly, additional studies are required to assess the influence of these predisposing factors on DNX efficacy.

Tolerability and toxicity
=========================

Production of liposomal anthracycline compounds was pioneered with the goal of producing therapeutics with higher specificity and potency while limiting patient side-effects. A major concern of any anthracycline treatment modality is cardiotoxicity. Both congestive heart failure and cardiomyopathy have been reported to occur in a dose-dependent manner upon DNR treatment ([@b55-ijn-2-277]; [@b87-ijn-2-277]). To prevent the significant complications associated with anthracycline cardiotoxicity, patient left ventricular ejection fraction (LVEF) is closely monitored. In general, individuals demonstrating an LVEF of less than 45% were excluded from all initial DNX studies ([@b40-ijn-2-277]; [@b85-ijn-2-277]). Direct comparison of cardiac function in patients treated with DNX vs ABV revealed no significant difference in LVEF during treatment ([@b40-ijn-2-277]). Only one report to date has documented any LVEF decline following DNX administration. Moreover, upon further review of the effected individual's case history, prior anterior myocardial infarct was noted ([@b40-ijn-2-277]). Thus, although cumulative doses in many trials reached levels of over 600 mg/m^2^ ([@b38-ijn-2-277], [@b40-ijn-2-277]; [@b85-ijn-2-277]; [@b72-ijn-2-277]; [@b91-ijn-2-277]), DNX fails to induce significant cardiotoxicity.

The most prominent DNX side-effect reported in all clinical trials was severe leukopenia, which was observed in 11%--17% of treatment cycles ([@b38-ijn-2-277]; [@b35-ijn-2-277]). Most notably, in one trial, 85% of patients receiving a dose of 60 mg/m^2^ DNX every 2 weeks experienced grade 3/4 neutropenia ([@b85-ijn-2-277]). Moreover, the increased incidence of leukopenia in DNX- vs ABV-treated individuals was statistically significant (p = 0.021) ([@b40-ijn-2-277]). To combat this adverse effect, hemopoietic growth factors (eg, granulocyte colony-stimulating factor, G-CSF) were administered following 15%--29% of DNX treatment cycles and appeared to be effective in limiting further leukopenia (Fugamalli 2000; [@b72-ijn-2-277]). Other severe DNX-specific side-effects were not observed.

DNX patients develop alopecia and neuropathy less frequently than those treated with other cytostatic regimens (p \< 0.0001) ([@b40-ijn-2-277]). No other significant differences were found between patients treated with liposomal DNR vs conventional chemotherapy ([@b40-ijn-2-277]). Specifically, nausea, fever, and fatigue were similar among treatment regimens ([@b40-ijn-2-277]). In several reports, fever, flushing, and back pain were reported within the first 5 minutes of DNX administration. However, patients were typically able to resume therapy at a slower infusion rate without significant distress ([@b40-ijn-2-277]). [Table 2](#t2-ijn-2-277){ref-type="table"} summarizes the complications observed in DNX trails for KS. Overall, DNX treatment appears to limit some of the adverse side-effects of conventional chemotherapy ([@b66-ijn-2-277]; [@b38-ijn-2-277], [@b39-ijn-2-277]; [@b35-ijn-2-277]; [@b72-ijn-2-277]).

Several clinical trials have monitored patient quality of life (QOL) during DNX treatment. During one study, both physical and emotional performance increased over 70% during DNX treatment ([@b66-ijn-2-277]). A second study comparing DNX with ABV showed that patients within the DNX study arm maintained QOL whereas QOL gradually declined with ABV treatment ([@b40-ijn-2-277]). Although the significance of these data is unclear, the trend suggests that DNX treatment may be more tolerable than conventional chemotherapy, especially during long-term treatment regimens.

Pharmacoeconomics
=================

When considering any new medical intervention, the costs of therapy must be weighed against the potential benefits. For aggressive KS, several treatment options are now available, including conventional chemotherapies (eg, ABV, BV, CHOP), interferon alpha, vinca alkaloids, taxanes, and liposomal anthracyclines (reviewed in [@b51-ijn-2-277]). In general, liposomal drug formulations are more costly than conventional chemotherapy and are at present unaffordable in the areas of greatest need such as in Africa. However, the potential for these drugs to significantly reduce the adverse effects of anthracyclines make them attractive. To date, no direct comparison of PLD (Doxil^®^) with DNX has been conducted for KS, yet an indirect comparison can be made assuming that the patient cohorts and response criteria are essentially the equal. In 2008, Bennett and colleagues used data from the DNX vs ABV ([@b40-ijn-2-277]) and PLD vs BV ([@b80-ijn-2-277]) trials to estimate the cost-effectiveness of each liposomal therapy. While DNX is clearly more affordable upfront (US\$538/cycle vs US\$1212/cycle with PLD) ([@b10-ijn-2-277]), the number of cycles required for response as well as the costs associated with G-SCF administration must be included in order to properly compare the two therapies. During DNX treatment a higher number of patients required granulocyte-colony stimulating factor (G-SCF) therapy, in addition an average of 8.6 cycles of DNX vs 4.8 cycles of PLD were necessary for patient response ([@b40-ijn-2-277]; [@b10-ijn-2-277]; [@b80-ijn-2-277]). Taking these factors into account, the cost of DNX treatment was still \~US\$445 less than PLD ([@b9-ijn-2-277]).

In both studies, patient outcome was monitored by ATCG standards at the conclusion of the trial. Response rates for PLD vs DNX were 59% and 25%, respectively ([@b40-ijn-2-277]; [@b80-ijn-2-277]). Due to this disparity among treatment regimens, the cost-effectiveness ratio (the cost associated with achieving one response) was twice as high for DNX (US\$26,483) as for PLD (US\$11,976) ([@b10-ijn-2-277]). In a study of Swedish patients, similar results were obtained, demonstrating that PLD is more cost effective than DNX for the treatment of KS ([@b42-ijn-2-277]).

Comments and conclusions
========================

Treatment of aggressive KS has long relied upon the activity of combination chemotherapy. Although largely successful, these treatments carry many serious side-effects. The arrival of the liposomal anthracycline formulations provides patients new therapeutic options to combat KS. Herein, we discussed the pharmacokinetics, efficacy, and tolerability of DNX in AIDS-associated KS patients. Although response rates varied between trials, DNX proved superior to conventional DNR treatment and comparable to ABV ([@b40-ijn-2-277]). The liposomal formulation stabilizes DNR, preventing rapid clearance and allowing more time for the drug to accumulate in KS lesions ([@b33-ijn-2-277]; [@b38-ijn-2-277]). Notably, as observed with other liposomal anthracycline formulations, cardiotoxicity is limited even in the presence of high cumulative DNR doses (≥500 mg/m^2^) ([@b38-ijn-2-277]; [@b40-ijn-2-277]; [@b85-ijn-2-277]). Although DNX costs less per cycle than other liposomal anthracyclines on the market, indirect comparison suggests that PLD is actually more cost-effective due to an increased response rate ([@b9-ijn-2-277]). As both prior chemotherapeutic treatment as well as CD4 count have been reported to influence patient response to DNX ([@b38-ijn-2-277]), it may be important to determine patient response in the context of naïve, CD4 high (\>100/μL) individuals. In this setting, DNX may show significant promise.

Currently Doxil (PLD) represents the major competitor to DNX therapy. In general, patient response to Doxil requires fewer treatment cycles and thus is more cost effective ([@b40-ijn-2-277]; [@b80-ijn-2-277]; [@b9-ijn-2-277]). It is clear that the pegylated, STEALTH^®^, formulation of Doxil further limits RES uptake, resulting in longer periods of drug circulation in vivo ([@b4-ijn-2-277]). Whether similar formulations of DNR would prove more efficacious in the treatment of KS is unclear since anthracyclines display virtually identical mechanistic properties. Importantly, each new advance in liposomal technology has increased drug efficacy, specificity and tolerability, leading to better therapeutic options for patients with KS.

Strikingly, the efficacy of DNX has been predominantly evaluated in the context of HIV-positive males. Although there is an urgency to develop more effective drugs for AIDS-associated KS, little is know about the effects of DNX on HIV-negative patients. Previous reports have observed no difference in the response rates of endemic vs epidemic KS to therapy ([@b79-ijn-2-277]; [@b48-ijn-2-277]). However, patient HIV status is sure to influence DNX efficacy as CD4 count significantly influences therapeutic outcome ([@b38-ijn-2-277]). Clinical trials have thus far failed to address DNX efficacy in females. In fact, less than 1% of DaunoXome study participants were female ([@b66-ijn-2-277]; [@b38-ijn-2-277], [@b39-ijn-2-277]; [@b85-ijn-2-277]; [@b35-ijn-2-277]). These data reflect the predominantly male HIV population at the outset of the AIDS epidemic in the US. To date, however, females account for almost half of the HIV-positive population world-wide ([@b67-ijn-2-277]; [@b86-ijn-2-277]). Over 25% of patients diagnosed with HIV in 2004 were women and this number continues to grow ([@b15-ijn-2-277]). In areas where KS is endemic and spread by non-sexual as well as sexual routes, KS is found in women and female children almost as frequently as in men. As women often display differential drug metabolics, it is essential that additional studies be conducted in female KS patients in order to clearly understand and assess DNX efficacy.

Finally, use of universal response criteria, such as those provided by the ATCG or recently proposed (CIT-NEJM), should greatly improve our ability to assess therapeutic efficacy. Proper assessment of visceral disease may require the advent of new technologies to improve KS detection and characterization. Additionally, future development of DaunoXome to decrease RES-uptake may be needed in order to compete with the pegylated anthracycline formulations currently on the market. Still, DNX clearly represents a significant advance in KS chemotherapy, providing multiple benefits over conventional, ABV-like therapies and potentially improving patient QOL.

![KS survival rates during the rise of the HIV/AIDS pandemic. Data bars represent the percentage of individuals reported by the NCI Surveillance Epidemiology and End Results (SEER) program to have survived 5 years post-diagnosis.](ijn-2-277f1){#f1-ijn-2-277}

![Structure of daunorubicin.](ijn-2-277f2){#f2-ijn-2-277}

![Structure of a STEALTH^®^ liposome. A soluble drug component such as daunorubicin is contained within a single lipid bilayer. Addition of polyethylene glycol polymers to the liposomal surface (STEALTH technology) leads to decreased RES uptake and increased drug stability (adapted from [@b4-ijn-2-277]).](ijn-2-277f3){#f3-ijn-2-277}

###### 

Aids Clinical Trials Groups response criteria for AIDS-releated Kaposi's sarcoma

  **Response classification**   **Tumor-associated edema**      **Lesions**                                                                                                                                                                                                                                                     **Visceral disease**                            **Required response duration**
  ----------------------------- ------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------
  Complete response (CR)        None                            None[1](#tfn1-ijn-2-277){ref-type="table-fn"}                                                                                                                                                                                                                   None[2](#tfn2-ijn-2-277){ref-type="table-fn"}   ≥4 weeks
  Partial response (PR)         No increase or new appearance   1\. ≥50% decrease in \# or size of previous lesions[3](#tfn3-ijn-2-277){ref-type="table-fn"} 2. No new lesions or areas of involvement 3. No increase ≥25% in the product of bidirectional indicator lesion diameter[º](#tfn4-ijn-2-277){ref-type="table-fn"}   No increase or new sites of involvement         ≥4 weeks
  Stable disease (SD)           Any non-PR response             Any non-PR response                                                                                                                                                                                                                                             Any non-PR response                             Not specified
  Progression                   New edema or effusion           1\. ≥25% increase in the size, \#, or sites of disease involvement 2. ≥25% change in lesion appearance from macular to plaque-like/nodular                                                                                                                      Any increase                                    Not specified

**Notes:** As described in [@b50-ijn-2-277] ^1^If brown/tan macular lesions persist, at least one representative must be biopsied and shown to be free of malignancy;

Verification by restaging is required, otherwise only a clinical CR may be declared;

Defined as a ≥50% decrease in the sums of the products of the largest perpendicular diameters of bidimensionally measurable marker lesions and/or complete flattening ≥50% of previously nodular lesions;

In patients with predominantly nodular lesions, flattening of ≥75% is considered PR.

###### 

Complications observed in clinical trials of liposomal daunorubicin

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Report**         **Overall response**   **Cardiotoxicity**                                                    **Neuropathy**   **Alopecia**    **Neutropenia**                    **Leukopenia**           **Fatigue**      **Nausea**       **Opportunistic infection**
  ------------------ ---------------------- --------------------------------------------------------------------- ---------------- --------------- ---------------------------------- ------------------------ ---------------- ---------------- -----------------------------
  [@b40-ijn-2-277]   29%                    1/116 showed LVEF decline[a](#tfn5-ijn-2-277){ref-type="table-fn"}\   Grade 1/2:12%\   Grade 1/2:8%\   Grade 1/2:67%\                     Grade 1/2:91%\           Grade 1/2:43%\   Grade 1/2:51%\   36%
                                            Other cardiac events:6.0%                                             Grade 3/4:1%     Grade 3/4:0%    Grade 3/4:51%                      Grade 3/4:38%            Grade 3/4:6%     Grade 3/4:3%     

  [@b38-ijn-2-277]   55%                    None observed                                                         0%               Grade 1:5%      17% of cycles                      NR                       Grade 1/2:59%    Grade 1/2:46%    NR

  [@b35-ijn-2-277]   82%                    No reduction of LVEF to below 50%                                     NR               NR              NR                                 11.1%--13.3% of cycles   NR               NR               0%

  [@b72-ijn-2-277]   38%                    No worsening or appearance of cardiac events                          NR               NR              29% of cycles required treatment   NR                       NR               NR               8%

  [@b66-ijn-2-277]   71%                    Observed only in patients with pre-existing heart conditions          NR               Grade 1:16%\    NR                                 NR                       NR               Grade 1/2:20%\   NR
                                                                                                                                   Grade 2--4:0%                                                                                Grade 3/4:0%     

  [@b85-ijn-2-277]   32%                    No decline in LVEF observed                                           NR               11%             Grade 3/4:85%                      NR                       54%              53%              NR
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patient case history showed previous myocardial infarct

**Abbreviations:** LVEF, left ventricular ejection fraction, NR, not reported.
